Future Science Group
2 files

Reduced risk of infections with the intravenous immunoglobulin, IgPro10, in patients at risk of secondary immunodeficiency-related infections. Supplementary data

posted on 2022-08-16, 08:08 authored by Gabriela Espinoza, Andrew S. Koenig, Yufei Song, Julien Heidt, Xiang Zhang, Rajiv Mallick, Betsy J. Lahue


Supplementary Table 1. Reduced odds for a severe infection in the follow up (post-index) period, with IgPro10, adjusting for covariates: A general linear model in matched cohorts* restricted to patients with at least 6 months of follow up.

Supplementary material 2: International Classification of Diseases, Ninth and Tenth Revision (ICD-9/10), Current Procedural Terminology (CPT), Healthcare Common Procedure Coding System (HCPCS) and RxNorm codes used for inclusion/exclusion in the study.